Robotic Surgery May Allow for Quicker Procedures With Less Radiation

Commentary
Video

The Epione robot may help less experienced surgeons carry out complex cases with a high level of accuracy, says Govindarajan Narayanan, MD.

Govindarajan Narayanan, MD, explained that the advent of the Epione surgical robot may be a precursor to future technological advancements in the world of surgical oncology, including the potential for practices to treat patients remotely and with less radiation.

In an interview with CancerNetwork®, Narayanan, a professor of Radiology and an interventional radiologist at Miami Cardiac and Vascular Institute and the chief of Interventional Oncology at Miami Cancer Institute, Baptist Health South Florida, described how Epione “levels the playing field” by making the surgical process quicker while potentially increasing the availability of physicians who can offer surgery to patients across centers. He said that practices in other countries have already been operating the surgical robot remotely, which would allow patients to undergo surgery at treatment centers even if a practicing physician is not there in-person.

Developers designed the Epione robot to streamline several probe procedures, thereby making treatment of large tumors via microwave ablation, cryoablation, irreversible electroporation, and other strategies more predictable.

Transcript:

[Epione] levels the playing field. It can bring less experienced users to do these procedures with a higher level of accuracy. That may improve the availability of physicians who can offer these treatments in multiple centers.

We are at the beginning of an exciting technology that’s being introduced in the space of image-guided ablation. In other countries, they’re using these robotic devices remotely; I feel that we will eventually get to the point where the science would allow us to operate on patients in remote locations, thereby improving access to these cutting-edge technologies in different institutions where they may not have the physician stationed there. [I see Epione] being able to help less experienced physicians do more complex cases with less radiation, quicker procedure times, and [the potential for] remote access. That is where I see this [technology] going.

Reference

Epione. Quantum Surgical. Accessed November 7, 2023. https://shorturl.at/dqyL6

Recent Videos
Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Related Content